- Home
- SDGR vs TIC Comparison
SDGR vs TIC Comparison
Compare SDGR & TIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDGR
- TIC
- Stock Information
- Founded
- SDGR 1990
- TIC 1991
- Country
- SDGR United States
- TIC United States
- Employees
- SDGR N/A
- TIC N/A
- Industry
- SDGR Biotechnology: Pharmaceutical Preparations
- TIC
- Sector
- SDGR Health Care
- TIC
- Exchange
- SDGR Nasdaq
- TIC Nasdaq
- Market Cap
- SDGR 1.5B
- TIC 1.5B
- IPO Year
- SDGR 2020
- TIC N/A
- Fundamental
- Price
- SDGR $20.56
- TIC $11.06
- Analyst Decision
- SDGR Buy
- TIC Hold
- Analyst Count
- SDGR 5
- TIC 1
- Target Price
- SDGR $32.80
- TIC $11.50
- AVG Volume (30 Days)
- SDGR 1.2M
- TIC 2.2M
- Earning Date
- SDGR 07-30-2025
- TIC 08-03-2025
- Dividend Yield
- SDGR N/A
- TIC N/A
- EPS Growth
- SDGR N/A
- TIC N/A
- EPS
- SDGR N/A
- TIC N/A
- Revenue
- SDGR $230,492,000.00
- TIC $1,108,546,000.00
- Revenue This Year
- SDGR $24.44
- TIC $4.52
- Revenue Next Year
- SDGR $22.17
- TIC $5.23
- P/E Ratio
- SDGR N/A
- TIC N/A
- Revenue Growth
- SDGR 22.29
- TIC 9.12
- 52 Week Low
- SDGR $16.60
- TIC $8.76
- 52 Week High
- SDGR $28.47
- TIC $14.28
- Technical
- Relative Strength Index (RSI)
- SDGR 38.35
- TIC N/A
- Support Level
- SDGR $20.04
- TIC N/A
- Resistance Level
- SDGR $20.88
- TIC N/A
- Average True Range (ATR)
- SDGR 1.24
- TIC 0.00
- MACD
- SDGR -0.28
- TIC 0.00
- Stochastic Oscillator
- SDGR 9.51
- TIC 0.00
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.